Innovent Biologics' G-HOPE-001 trial confirms clinical efficacy for its ADC candidate, marking a major milestone for the company's oncology pipeline and potential market expansion.
Innovent Biologics' lead ADC candidate, Arcotatug Tavatecan, successfully met both primary endpoints of overall survival and progression-free survival in the Phase 3 G-HOPE-001 study. This clinical success in treating CLDN18.2-positive gastric cancer validates the company's oncology pipeline and positions the drug for potential regulatory approval and commercialization.
The study met both primary endpoints, showing statistically significant and clinically meaningful benefits in overall survival and progression-free survival.
The drug is targeted at patients with previously treated, CLDN18.2-positive gastric cancer.
Innovent Biologics reported positive Phase 3 results for its lead ADC candidate, Arcotatug Tavatecan, in patients with CLDN18.2-positive gastric cancer. The study met both primary endpoints, showing statistically significant improvements in overall survival and progression-free survival.
The successful trial validates the efficacy of Arcotatug Tavatecan, providing a clear path for regulatory submission and potential commercialization in the gastric cancer market.